Ubrelvy Shortage: What Providers and Prescribers Need to Know in 2026

If your migraine patients are reporting difficulty filling Ubrelvy (ubrogepant) prescriptions, the challenge is real — even though the drug is not on the FDA's official shortage list. As a prescriber, understanding the landscape in 2026 will help you anticipate barriers, counsel patients appropriately, and reduce prescription abandonment. This briefing covers what you need to know.

Clinical Background: Ubrelvy in the Acute Migraine Landscape

Ubrelvy (ubrogepant) received FDA approval on December 23, 2019, for the acute treatment of migraine with or without aura in adults. It was the first oral CGRP receptor antagonist (gepant) approved for this indication. Its manufacturer, AbbVie (formerly Allergan), continues to produce it.

Key clinical characteristics that influence prescribing decisions:

Dosing: 50 mg or 100 mg orally as needed. A second dose may be taken ≥2 hours after initial dose. Maximum 200 mg in 24 hours. Safety not established beyond 8 migraines per 30 days.

Mechanism: CGRP receptor antagonism. No vasoconstriction. Safe in patients with cardiovascular disease or vascular contraindications to triptans.

Controlled substance: Not a controlled substance. No DEA scheduling. No driving restriction.

Key drug interactions: Contraindicated with strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, nirmatrelvir/ritonavir). Dose adjustment required with moderate CYP3A4 inhibitors (verapamil, diltiazem) and moderate inducers. Grapefruit: dose adjustment needed.

Monitoring: Blood pressure check 2–4 weeks after initiation recommended due to risk of new-onset or worsening hypertension. Monitor for Raynaud's phenomenon.

Supply Status: Is There an Ubrelvy Shortage in 2026?

No. As of 2026, Ubrelvy is not listed on the FDA's Drug Shortages database. AbbVie continues to manufacture and distribute the medication. Patient access difficulties are not caused by manufacturing disruption.

The access barriers are primarily:

High cost: WAC of $1,139.09 per 30-day supply as of January 2026. No generic available until at least 2035.

Insurance: Most plans require prior authorization and/or step therapy (trial of two or more triptans). ACA plans: ~80% of enrollees require step therapy. Medicare coverage varies by Part D plan.

Pharmacy stocking: Inconsistent at retail chains, particularly in smaller markets.

Prior Authorization: What Prescribers Need to Document

Most payers require documentation of step therapy before approving Ubrelvy. A strong PA submission typically includes:

Confirmed diagnosis of migraine with or without aura (ICD-10: G43.0, G43.1, or G43.909)

Documentation of failed or contraindicated triptan trial(s) — typically two different triptans

For cardiovascular patients: documentation of why triptans are contraindicated (vasoconstriction risk)

Clinical notes supporting Ubrelvy as medically necessary for this patient

For patients who need Ubrelvy immediately while PA is pending: the Ubrelvy Complete Savings Card program allows up to 2 months of free fills for commercially insured patients while coverage review is ongoing.

Clinical Alternatives to Consider

When Ubrelvy is unavailable or unaffordable, evidence-supported alternatives include:

Nurtec ODT (rimegepant, 75 mg): Same CGRP class; FDA-approved for both acute and preventive treatment of episodic migraine. Useful when prevention is also a goal.

Zavzpret (zavegepant, 10 mg intranasal): CGRP antagonist; useful for patients with nausea/vomiting or who prefer non-oral administration.

Generic triptans: Sumatriptan, rizatriptan, eletriptan — effective first-line options for patients without cardiovascular contraindications. Generic pricing starts at $10–$30 per 9 tablets with discount coupons.

Dihydroergotamine (DHE): For refractory cases; available as nasal spray (Migranal) and injectable forms.

Patient Cost Resources to Share With Your Patients

Ubrelvy Complete Savings Card: As little as $0/month for commercially insured patients; max $7,000/year. ubrelvy.com/savings or 1-844-577-6239.

myAbbVie Assist: Patient assistance program for uninsured or underinsured patients with limited income; up to 12 months of medication at no charge.

GoodRx / SingleCare: Discount coupons that can reduce cash price to approximately $970–$1,050 for 10 tablets.

Helping Patients Find Ubrelvy in Stock

One common patient complaint is that even when coverage is resolved, they can't find a pharmacy that has Ubrelvy in stock. Integrating medfinder for providers into your prescribing workflow can reduce prescription abandonment. medfinder calls pharmacies near the patient to identify which ones have the medication in stock — a significant time-saver for patients already managing a chronic neurological condition.

Summary: Key Takeaways for Prescribers

No FDA shortage in 2026; manufacturing is normal

Access barriers are insurance-related (PA, step therapy) and cost-related (no generic, $1,100+/month list)

Proactive PA documentation reduces delays; AbbVie offers bridge fills while PA is pending

Monitor BP and watch for Raynaud's in patients starting Ubrelvy

Recommend the Ubrelvy Complete Savings Card to all commercially insured patients

For a practical guide on how to support patients with the medication-finding process, see our companion article: How to Help Your Patients Find Ubrelvy in Stock: A Provider's Guide.